The Long-Term Influence of Tissue Inhibitor of Matrix Metalloproteinase-1 in Patients with Mild to Moderate Coronary Artery Lesions in a Chinese Population: A 7-Year Follow-Up Study

Cardiology (Switzerland)

Volumn 132, Issue 3, 2015, Pages 151-158

  Wang, Wei ^a,b   Song, Xiantao ^a,b   Chen, Yundai ^c   Yuan, Fei ^a,b   Xu, Feng ^a,b   Zhang, Min ^a,b   Tan, Kai ^a,b   Yang, Xingsheng ^a,b   Yu, Xianpeng ^a,b   Lv, Shuzheng ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF HEART   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Coronary artery disease; Matrix metalloproteinase 9; Prognosis; Tissue inhibitor of metalloproteinase 1

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER; MMP9 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; ADVERSE OUTCOME; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CHINESE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; BLOOD; CHINA; CORONARY BLOOD VESSEL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; BIOMARKERS; CHINA; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84939518294     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000430885     Document Type: Article

References (32)

1. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, Guralnik JM, Longo DL: The origins of age-related proinflammatory state. Blood 2005; 105: 2294-2299.
3. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262.
4. Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ: Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004; 42: 121-131.
5. Fingleton B: Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007; 13: 333-346.
6. Ikonomidis JS, Gibson WC, Butler JE, McClister DM, Sweterlitsch SE, Thompson RP, Mukherjee R, Spinale FG: Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms. Circulation 2004; 110:II268-II273.
7. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
8. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, Cicero AF: Matrix metalloproteinase-2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13: 227-231.
9. Nagase H, Suzuki K, Itoh Y, Kan CC, Gehring MR, Huang W, Brew K: Involvement of tissue inhibitors of metalloproteinases (TIMPs) during matrix metalloproteinase activation. Adv Exp Med Biol 1996; 389: 23-31.
10. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
11. Marchesi C, Dentali F, Nicolini E, Maresca AM, Tayebjee MH, Franz M, Guasti L, Venco A, Schiffrin EL, Lip GY, Grandi AM: Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens 2012; 30: 3-16.
12. Kramer F, Milting H: Novel biomarkers in human terminal heart failure and under mechanical circulatory support. Biomarkers 2011; 16(suppl 1):S31-S41.
13. Kelly D, Squire IB, Khan SQ, Dhillon O, Narayan H, Ng KH, Quinn P, Davies JE, Ng LL: Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction. Am J Cardiol 2010; 106: 477-482.
14. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Wilson PW, Vasan RS: Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart Study. Eur Heart J 2004; 25: 1509-1516.
15. Zeng S, Zhou X, Tu Y, Yao M, Han ZQ, Gao F, Li YM: Long-term MMP inhibition by doxycycline exerts divergent effect on ventricular extracellular matrix deposition and systolic performance in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 2011; 33: 316-324.
16. Kukacka J, Bibova J, Ruskoaho H, Pelouch V: Protein remodeling of extracellular matrix in rat myocardium during four-day hypoxia: the effect of concurrent hypercapnia. Gen Physiol Biophys 2007; 26: 133-142.
17. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78: 1157-1166.
18. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators: A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364: 226-235.
19. Lambert E, Dasse E, Haye B, Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187-198.
20. Ries C: Cytokine functions of TIMP-1. Cell Mol Life Sci 2014; 71: 659-672.
21. Vanhoutte D, Heymans S: TIMPs and cardiac remodeling: 'embracing the MMP-independent-side of the family'. J Mol Cell Cardiol 2010; 48: 445-453.
22. Uchinaka A, Kawaguchi N, Mori S, Hamada Y, Miyagawa S, Saito A, Sawa Y, Matsuura N: Tissue inhibitor of metalloproteinase-1 and-3 improves cardiac function in an ischemic cardiomyopathy model rat. Tissue Eng Part A 2014; 20: 3073-3084.
23. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR: Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-2096.
24. Franz M, Berndt A, Neri D, Galler K, Grun K, Porrmann C, Reinbothe F, Mall G, Schlattmann P, Renner A, Figulla HR, Jung C, Kuthe F: Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B(+) tenascin-C and ED-A(+) fibronectin in dilated cardiomyopathy: potential impact on disease progression and patients' prognosis. Int J Cardiol 2013; 168: 5344-5351.
25. Hamed GM, Fattah MF: Clinical relevance of matrix metalloproteinase 9 in patients with acute coronary syndrome. Clin Appl Thromb Hemost 2015, pii: 1076029614567309.
26. Lubos E, Schnabel R, Rupprecht HJ, Bickel C, Messow CM, Prigge S, Cambien F, Tiret L, Munzel T, Blankenberg S: Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 2006; 27: 150-156.
27. West MJ, Nestel PJ, Kirby AC, Schnabel R, Sullivan D, Simes RJ, Pollicino C, Lubos E, Munzel TF, White HD, Tonkin AM, Bickel C, Tiret L, Blankenberg S: The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J 2008; 29: 923-931.
28. Zayani Y, Allal-Elasmi M, Jacob MP, Zidi W, Zaroui A, Feki M, Mourali S, Mechmech R, Kaabachi N: Peripheral blood levels of matrix and inflammatory mediators are elevated in Tunisian patients with acute coronary syndromes. Clin Lab 2013; 59: 169-175.
29. Opstad TB, Arnesen H, Pettersen AA, Seljeflot I: The MMP-9-1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease. PLoS One 2014; 9:e106816.
30. Mishra A, Srivastava A, Mittal T, Garg N, Mittal B: Genetic predisposition to left ventricular dysfunction: a multigenic and multi-analytical approach. Gene 2014; 546: 309-317.
31. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V: Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12: 56-62.
32. Bahr RD, Leino EV, Christenson RH: Prodromal unstable angina in acute myocardial infarction: prognostic value of short-and longterm outcome and predictor of infarct size. Am Heart J 2000; 140: 126-133.